Knowledge Management Advisory Board

Driving best practices around knowledge management for the Pharma industry

KMAB

Our Mission

To define and help implement industry best practices for knowledge
management that leads to good insights and decisions at scale.
Awesome Image Awesome Image

Highlight

Highlight the importance of knowledge management in strategic decision making.

Awesome Image Awesome Image

Improve

Improve the culture of decision making at healthcare companies.

Awesome Image Awesome Image

Elevate

Ensure people who are improving knowledge management are elevated.

Join the Discussion: Knowledge Management and Decision Making in Pharma and Biotech

Following the publication of its first paper “Selecting A Compound For Drug Development – The Importance Of Knowledge Management”, the KMAB is building a community for discussion and information sharing.

 

Selecting A Compound For Drug Development – The Importance Of Knowledge Management

Download the KMAB’s paper

Take our 10-minute survey about drug development timing and the roles Total Product Profile, AI, and knowledge management play within your organization:

Take Survey

Register for related webinars:

Webinar 1

 May 6, 2024 at 3pm Eastern

Register here

Webinar 2

June 5, 2024 at 12pm Eastern

Register here

Upcoming In-person Panel Discussions:

Join our KMAB LinkedIn Group

Our Background

At inPhronesis, we care a lot about knowledge management and we want to help the industry as a whole to improve its decision making. We also believe we shouldn't be developing a product in a vacuum. This led us to build the Knowledge Management Advisory Board (KMAB) and to make sure that we include both existing customers as well as outside experts and even people outside our industry, who can help to research and drive improvements in how knowledge management can help drive strategic decision making.

Our Work

The Knowledge Management Advisory Board recently published their first collaborative paper, "Selecting A Compound For Drug Development – The Importance Of Knowledge Management.” Two accompanying webinars also occurred. The whitepaper and archived webinars can be viewed on our Insights page.

Awesome Image

Meet The Advisory Board:

Diana Gowe Kolek

Global Strategic Analytics, J&J

Read Bio

John Panaccione

Co-Founder, Folla Capital

Read Bio

Anna Skabeev

Sr. Director Global Alliance Management, Teva

Read Bio

Hari Patel

Sr. Director Portfolio & Product Development, BioMarin

Read Bio

Kelly Knauth

Director Commercial Insights, AbbVie

Read Bio

John McDonald-Dick

Global Head of Competitive Intelligence, UCB

Read Bio

An AI-driven platform built specifically for life sciences designed to enhance efficiency by organizing, evaluating, visualizing, & sharing insights from pipeline, market landscape and clinical data.

Linkedin
Quick Links
Get In Touch
Our Family Of Companies​

Privacy Policy

Terms of Service

Vulnerability

© 2024 inPhronesis. All Rights Reserved.

Diana Gowe Kolek

Global Strategic Analytics, J&J

Diana provides leadership and strategic direction to the Global Commercial Insights & Analytics team. She’s responsible for driving functional excellence and efficiency in competitive intelligence, championing talent, and implementing compliant processes across GCSO (Global Commercial Strategy Organization).  As a strategic partner, Diana partners across the GCSO Therapeutic Area (TA) analytics group and leaders to determine appropriate functional methodologies and capabilities to support emerging and existing business drivers and trends. She also oversees management of internal and external data sources, tools & budgets.

 

Diana joined Janssen in 2001 and spent 7 years at Ortho McNeil Pharmaceuticals, where she provided business intelligence in support of the CNS franchise. In 2009 she transitioned to the Global Commercial Strategy Organization where she built the Global Business Intelligence Function. She is now part of the Portfolio, Innovation & Commercialization Strategy team. Prior to joining Johnson & Johnson, she spent 17 years at Knoll Pharmaceuticals in roles of increasing responsibility, delivering scientific and business intelligence. Diana holds a Masters Degree in Library and Information Science from Rutgers University, and a Bachelor’s Degree in Health Sciences from William Paterson University.

John Panaccione

Co-Founder, Folla Capital

John Panaccione is the co-founder of Folla Capital; an SEC-registered broker-dealer focused on helping small businesses and startups raise capital. He holds Series 7 (General Securities Representative), 24 (General Securities Principal), 79 (Investment Banking), and 63 (Uniform Securities Agent State Law) SEC licenses. Before launching Folla Capital in 2020, he co-founded and led a software company called the LogicBay Corporation from its launch in 2003 to its sale to Pluribus Technologies in 2020. During that time, he learned everything there is to know about the challenging world of small business finance the only way you can – the hard way - by doing.

Along the way, in 2013, John also co-founded a non-profit VETtoCEO with another Army veteran-turned-business-owner. VETtoCEO’s mission is to help transitioning military members explore small business ownership as a viable career path when leaving military service. In 2022, he merged VETtoCEO with Warrior Rising. Before catching the entrepreneurial bug, he worked in operations and sales leadership roles in several small and large corporations. John proudly served as a U.S. Army officer for six years, mostly in various leadership roles in paratrooper units in the 82nd Airborne Division. He earned a B.S. in Criminal Justice and an M.B.A. with a Management of Technology and Operations focus, both from Bryant University.

Anna Skabeev

Anna Skabeev, MD, MBA is a strategic leader with over 15 years in the biopharma industry, with experience supporting products across life cycle, as well as working across alliances. Most recently, she was a Senior Director, Alliance Management at Karyopharm Therapeutics. Prior to joining Karyopharm Anna was at Sanofi Genzyme leading a global competitive intelligence team for DUPIXENT across indications. Anna also held competitive intelligence (CI) roles at Biogen and Ironwood.

Through her experience in CI, Anna became passionate about knowledge management solutions that enable timely and actionable decision-making and provided input into inVision in its early development stage.

Anna’s other roles in the biopharma industry included patient engagement, clinical trial recruitment, decision support and marketing. Anna has an MD from St. Petersburg Pediatric Medical Academy in Russia and an MBA from Suffolk University, Boston, MA.

Hari Patel

Sr. Director Portfolio & Product Development, BioMarin Pharmaceutical Inc.

Hari is a Core Team Leader at BioMarin, a mid-size rare disease company. As a cross-functional leader, he works across modalities and life-cycle management for pipeline and launched therapeutics. Hari has held progressive leadership roles over his 20+ years within the industry. Hari spent nine years at Genentech building the Market Analytics and Strategy group. He led immunology, ophthalmology, and non-onc commercial strategy and planning teams to defend against competitor and biosimilar launches. Before Genentech, Hari held roles in Sales, Global Marketing, Corporate Strategy, and Business Development.

Hari holds an MBA, an MHA, and a Bachelor of Science in Biology from the University of Pittsburgh. He resides in the east bay with his wife, Reena, and two kids.

Kelly Knauth

Director Commercial Insights, AbbVie

Kelly Knauth, M.S., is an accomplished pharmaceutical industry professional. Currently serving as the Director of Commercial Insights at AbbVie, playing a crucial role in making significant contributions to the company's strategic vision and market understanding.

Prior to joining AbbVie, Kelly spent time at Abbott Laboratories, where he led the market insights team responsible for several therapeutic areas, including Endocrinology, MBO, Neuroscience, Oncology, Renal, and Virology. Kelly developed methodologies for forecasting the impact of legislative changes and contributed to the identification of licensing and co-promotion targets. Kelly was also instrumental in the development of life cycle management strategies for assets.

Kelly's experience also includes Covidien/Mallinckrodt Pharmaceuticals, where he led New Product Planning and Business Development. In this role, Kelly ensured the timely launch of pipeline products and led the charge on market analyses and franchise strategy recommendations. Prior, Kelly held positions at Eli Lilly and Company, assessing the financial value of opportunities and creating productivity metrics for the business development group.

Kelly's diverse background also includes roles at GD Searle as an Epidemiologist/Market Research Analyst and at the American College of Healthcare as a Research Assistant.

John McDonald-Dick

Global Head of Competitive Intelligence, UCB

John McDonald-Dick is a pharmaceutical industry leader, specializing in competitive intelligence. Currently serving as the Global Head of Competitive Intelligence at UCB, John plays a crucial role in shaping UCB's competitive landscape. His strategic vision and analytical skills contribute significantly to UCB's success in navigating challenges and seizing emerging opportunities in the healthcare industry.

Before joining UCB, John held senior positions at Takeda, Physeon, Novintum Bioscience, and Rising Tide where he made key contributions in Regulatory Intelligence, Clinical Affairs, Operations and Commercial Development.

Throughout his career, John has showcased an ability to analyze market trends, competitor activities, and industry dynamics. His proficiency extends beyond traditional competitive analysis, encompassing a profound understanding of the pharmaceutical and biopharmaceutical sectors.

Contact us

Learn how inPhronesis can simplify your life and empower your team with expert consultants and our cloud-based system, inVision.

Chris Martin, MBA, MS

President

As the president of inPhronesis, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.

 

With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.

 

Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.